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Abstract
Background: In protein drug development, in vitro molecular optimization or protein maturation can be used to
modify protein properties. One basic approach to protein maturation is the introduction of random DNA
mutations into the target gene sequence to produce a library of variants that can be screened for the preferred
protein properties. Unfortunately, the capability of this approach has been restricted by deficiencies in the
methods currently available for random DNA mutagenesis and library generation. Current DNA based
methodologies generally suffer from nucleotide substitution bias that preferentially mutate particular base pairs
or show significant bias with respect to transitions or transversions. In this report, we describe a novel RNA-
based random mutagenesis strategy that utilizes Qβ replicase to manufacture complex mRNA libraries with a
mutational spectrum that is close to the ideal.
Results: We show that Qβ replicase generates all possible base substitutions with an equivalent preference for
mutating A/T or G/C bases and with no significant bias for transitions over transversions. To demonstrate the
high diversity that can be sampled from a Qβ replicase-generated mRNA library, the approach was used to evolve
the binding affinity of a single domain VNAR shark antibody fragment (12Y-2) against malarial apical membrane
antigen-1 (AMA-1) via ribosome display. The binding constant (KD) of 12Y-2 was increased by 22-fold following
two consecutive but discrete rounds of mutagenesis and selection. The mutagenesis method was also used to
alter the substrate specificity of β-lactamase which does not significantly hydrolyse the antibiotic cefotaxime. Two
cycles of RNA mutagenesis and selection on increasing concentrations of cefotaxime resulted in mutants with a
minimum 10,000-fold increase in resistance, an outcome achieved faster and with fewer overall mutations than in
comparable studies using other mutagenesis strategies.
Conclusion: The RNA based approach outlined here is rapid and simple to perform and generates large, highly
diverse populations of proteins, each differing by only one or two amino acids from the parent protein. The
practical implications of our results are that suitable improved protein candidates can be recovered from in vitro
protein evolution approaches using significantly fewer rounds of mutagenesis and selection, and with little or no
collateral damage to the protein or its mRNA.
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There is a growing demand by the pharmaceutical and
medical industries for protein molecules, including anti-
bodies, of diagnostic and therapeutic efficacy, as well as a
perpetual need in the production and manufacturing
industries for improved biocatalysts. These demands have
directed the innovation of a number of sophisticated and
complex methods for the in vitro evolution and optimiza-
tion of proteins [1]. One fundamental approach to this
process is the introduction of random mutations into a
known nucleotide sequence to produce a library of vari-
ants. These variants are subsequently translated to pro-
duce modified proteins that are accordingly screened for
chosen properties.
The potential of this approach has been limited by defi-
ciencies in the methods currently available for random
mutagenesis and library generation [2]. Current methods
exclusively target DNA, and include error-prone PCR (EP-
PCR) [3], the incorporation of triphosphate derivatives of
nucleoside analogues with Taq or other DNA polymerases
[4] and novel error-prone DNA polymerases or polymer-
ase blends [5,6]. Unfortunately, DNA-based mutagenesis
systems generally suffer from a nucleotide incorporation
bias that favors transitions over transversions and/or
results in a skewed preference for mutations at either A/T
or G/C pairs [7,8]. Without doubt, base substitution bias
will diverge the distribution of mutations from a Poisson
distribution, effectively diminishing the functional size of
a randomly mutated gene library available for subsequent
screening [9]. In essence, any nucleotide bias reduces the
probability for generating specific amino acid substitu-
tions that may be required at key positions along the pro-
tein, dramatically reducing the potential for recovering
protein variants with a desired set of properties. Directed
protein evolution using powerful selection strategies such
as ribosome display (described below) are more likely to
identify improved variants when a library is maximally
diverse which would be the case when all variants in a
library are equally probable [10].
We have exploited Qβ bacteriophage RNA replicase, an
error-prone RNA-dependent RNA polymerase, and its
ability to amplify and mutate RNA very rapidly, to
develop an in vitro mutagenesis strategy targeting mRNA.
We have found that base substitutions at the RNA level are
made with very little bias for the incorporation of particu-
lar bases, approaching what can be considered as ideal
random mutagenesis. The result is the generation of ran-
dom mRNA libraries carrying very high diversity.
To verify that Qβ replicase manufactured variant mRNA
libraries can be highly effective tools for in vitro protein
evolution, two basic demonstrations are presented here.
First, Qβ replicase mutagenesis in combination with a
simple functional assay was used to alter the substrate spe-
cificity of β-lactamase for the antibiotic cefotaxime. And
second, Qβ mRNA mutagenesis coupled to ribosome dis-
play was used to enhance the affinity of a single domain
antibody fragment (VNAR) to its antigen. Ribosome dis-
play is an in vitro display and selection strategy that cou-
ples the newly translated protein to the ribosome
complex, which in turn, remains tethered to the mRNA
message due to the absence of a stop codon on the mRNA
(effectively linking phenotype to genotype). An mRNA
library can be translated in vitro and the ribosome-protein-
mRNA complexes can be subsequently screened (panned)
for binding towards the appropriate molecule and non-
specific or weaker binding complexes removed by exten-
sive washing. [11,12]. The mRNA is eluted from the
remaining (bound) ribosome complexes and amplified
with RT-PCR. Ribosome display, in particular, is ideal for
the effective screening of large mRNA libraries, with the
number of variants that can be screened limited only by
the total number of ribosomes in solution (estimated to
be up to 1014/ml typically found with in vitro eukaryotic
reticulocyte lysate systems) and the total amount of
mRNA that can be added to the translation mix [13].
Results
Constructing the Qβ replicase mutagenesis and ribosome 
display vectors
Developing a vector that would allow for the routine
application of Qβ replicase for the amplification of target
mRNA that could also subsequently be used directly in
ribosome display was not straightforward. As Qβ phage
has a double-stranded RNA genome, Qβ replicase has a
strong bias for replicating its own genome with both RNA
(-) and (+) strands serving as templates [14,15]. To adapt
this stringent template preference and allow replication of
foreign RNAs, pEGX216, a universal mutagenesis vector
(Figure 1A) was constructed based around a small multi-
cloning site (MCS) inserted into a modified RQ 135-1(-)
sequence. The RQ 135-1(-) sequence is the result of a
spontaneous recombination of E. coli 23 S RNA and the
phage λ origin of replication with the resulting sequence
efficiently recognized and amplified by Qβ-replicase [16-
18]. The integrated MCS did not appear to perturb the sec-
ondary structure required by Qβ-replicase to recognize the
RNA template. An upstream T7 RNA polymerase pro-
moter sequence on pEGX216 was used to synthesize RNA
suitable for Qβ-replicase.
For the coupling of mutagenesis to ribosome display,
pEGX216 was modified to generate a dual purpose muta-
genesis/ribosome display vector (pEGX253) by adding
various elements required for efficient translation and for
tethering the mRNA to the ribosome complex (see meth-
ods and Figure 1A). The mRNA transcribed from this vec-
tor was subsequently mutated with Qβ replicase, heatPage 2 of 12
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Note that the 5'-UTR, the Kozak sequence, the target gene,
and the CL region were cloned in the reverse orientation
relative to the T7 promoter to avoid intrinsic stop codons
found in our modified RQ 135-1(-) sequence. A prerequi-
site for ribosome display is that there are no stop codons
downstream of the translational start signal. Conse-
quently, the target gene sequence, the CL tether, and the
downstream segment of our modified RQ sequence
(which also forms part of the final tether) could not
include a translational stop codon. However, stop codons
are found in all three frames of the 3' segment of the RQ
135-1(-) sequence but in only two frames of the 5' seg-
ment. By cloning into the appropriate frame in the reverse
Qβ replicase mutagenesis/ribosome display vector and typical Qβ replicase amplification reactionFigure 1
Qβ replicase mutagenesis/ribosome display vector and typical Qβ replicase amplification reaction. (A): Sche-
matic representation of plasmid pEGX253. Base plasmid pEGX216 (elements depicted with underline) comprised of a MCS site 
inserted into a modified RQ 135-1(-) sequence which was then used to add the required elements to construct pEGX253. Tar-
get gene sequence (12Y-2) was cloned into the NcoI and NotI restriction sites. (B): Product from a typical Qβ replicase ampli-
fication of RGS mRNA. Lane 1 represents the amount of RGS single-stranded mRNA (-) template added to the Qβ replicase 
reaction. Lane 2 shows the Qβ replicase reaction product following amplification for 2 hrs at 37°C. Note that Qβ replicase 
amplifies both (-) and the newly generated (+) strands of the RNA eventually leading to a dsRNA product.
HindIII XhoI SacII NotI NcoI SfiI XhoI SmaI
pEGX253
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avoided down stream of the translational start codon. Qβ
replicase amplifies RNA in both directions, using both the
(+) and (-) RNA strands as templates, consequently,
mRNA in the correct orientation for translation and ribos-
ome display was innately generated following Qβ repli-
case mutagenesis (Figure 2). Note that due to the
replication of both (+) and (-) RNA strands, replication of
the starting template would be expected to be limited to
one round of replication that would stall when inert RNA
duplexes are eventually formed by annealed (+) and (-)
strands. However, the RQ 135-1(-) sequence contains
highly developed secondary structures that have been pos-
tulated to prevent complementary (+) and (-) strands of
RNA from annealing to each other during replication
leading to efficient and very rapid replication [19,20]. This
property also appears to be important with respect to
translation. Ugarov and collegues [17] found that the
expression of mRNAs in cell-free translation systems was
greatly enhanced as a result of their insertion into RQ135
RNA, again partly attributed to the very stable tertiary
structure of the RQ135 RNA. We have found that Qβ rep-
licase amplified mRNA, upon heat denaturing (see mate-
rials and methods), was a suitable template for translation
without the need to further purify and isolate the correct
strand for translation.
The mutational spectrum of Qβ replicase
A 500 base pair random gene sequence (RGS) from
Escherichia coli was used as a model template to establish
the mutational spectrum of Qβ replicase and to compare
this with the mutational profiles generated by other muta-
genesis methods. The 500 bp RDS had a GC content of
53% and did not contain any unusually long stretches of
any particular nucleotide. The RGS was embedded into
the RQ 135-1(-) sequence via the MCS of pEGX216. The
mRNA synthesized from this template was subsequently
amplified and mutated with Qβ replicase (Figure 1B). The
mutated mRNA was converted to cDNA using RT-PCR and
cloned. Random clones were selected and sequenced.
Under the conditions outlined here, the Qβ replicase error
rate was approximately 1 substitution in every 700 bases.
The data in Figure 3 demonstrates that Qβ replicase sub-
stituted bases randomly across the target template with no
obvious hot spots or clustering around particular
sequences. Qβ replicase showed an equal preference for
inserting A/T or G/C changes, with minimal bias for tran-
sitions over transversions (Figure 4A, 4B).
The background error rate (i.e. the mutation rate without
Qβ replicase) was measured by sequencing 24,000 base-
pairs from the control reaction. Only a single point muta-
tion was detected which was consistent with the predicted
error rate expected from a combination of Taq DNA
polymerase (the highest error rate documented for Taq
DNA polymerase in the literature is in the order of ~2 ×
10-4 [8]) and the error rate contributed by reverse tran-
scriptase (Superscript III™ reverse transcriptase error rate is
3.4 × 10-5 [21]). Together, Taq DNA polymerase and
Superscript III™ did not significantly contribute to the
observed mutation rate seen with Qβ replicase which in
this example was in the order of ~7 × 10-2.
The mutational spectrum of Qβ replicase compiled on the
RGS was directly compared with three DNA-based proto-
cols traditionally used to randomly mutate DNA and gen-
erate variant libraries. Two common protocols of EP-PCR
(with and without unbalanced concentrations of dGTP)
and MutazymeR II DNA polymerase (Mut II), a recent
blend of two different error-prone polymerases that is
claimed to produce an even, non-biased spread of muta-
tions (Stratagene), were used to mutate the RGS as out-
lined above. Our analysis showed that EP-PCR exhibited
a typical and well documented bias for A/T over G/C
changes and a strong preference for transitions over trans-
versions [7,8]. Both EP-PCR protocols gave similar muta-
tion patterns. Mut II showed a somewhat reduced
preference for transitions over transversions but still
strongly favored A/T changes over G/C changes (Figure
4A, 4B).
Figure 4C further dissects the data into the individual base
substitutions generated with each of the methods. All pos-
sible base substitutions were recovered with Qβ replicase
and the frequency of all possible transversion substitu-
tions were generally evenly spread. Mut II tended to favor
A/T to T/A transversions with the G/C -> C/G transversion
recovered only once within the data set. EP-PCR failed to
generate many of the possible transversions and showed a
distinct preference for A or T changes. All of the methods
tended to favor A/T to G/C transitions over G/C to A/T
transitions, with EP-PCR showing the greatest bias and Qβ
replicase showing the least bias.
Using RNA-based mutagenesis to engineer the specificity 
of TEM-1 β-lactamase
As an example of the efficacy of Qβ replicase for generat-
ing diverse mRNA libraries, and to provide a direct com-
parison with published reports of protein evolution using
other mutagenesis methods, Qβ replicase mutagenesis
was used to modify the well-characterized TEM-1 β-lacta-
mase antibiotic resistance protein of E. coli. Although
TEM-1 β-lactamase has broad substrate specificity [22], it
can not efficiently hydrolyze the extended-spectrum, third
generation cephalosporin, cefotaxime [23]. For instance,
when wild-type β-lactamase is expressed in E. coli from the
plasmid pUC19, the minimum inhibitory concentration
(MIC) for cefotaxime is 0.02 ug/ml. To modify the ability
of β-lactamase to hydrolyze cefotaxime, the protein cod-
ing sequence was cloned from the plasmid pUC19 intoPage 4 of 12
(page number not for citation purposes)
BMC Biotechnology 2007, 7:18 http://www.biomedcentral.com/1472-6750/7/18pEGX216, transcribed to synthesize mRNA, and the
mRNA was then mutated with Qβ replicase. The mutated
mRNA was converted to cDNA using reverse transcriptase,
cloned into a modified pUC19 plasmid (from which the
wild-type TEM-1 gene had previously been deleted down-
stream of the original pUC19 wild-type TEM-1 promoter
sequence) and transformed into E. coli. Clones were
selected for growth on agar plates containing increasing
concentrations of cefotaxime.
Resistant colonies chosen after the first round of mutagen-
esis and selection had a MIC of 20 ug/ml (i.e. growth on
plates containing 20 ug/ml cefotaxime) indicating a 1000-
fold increase in cefotaxime resistance. Ten clones in total
were sequenced yielding five variants. All clones carried
the G238S amino acid substitution with 2 clones showing
no other mutations. Five clones carried two mutations;
E104K and G238S (both G->A transitions). The remain-
ing 3 clones carried the G238S mutation in combination
with either F22S (A->G), H153R (A->G) or S267G (T->C).
These five variants were used as the basis for the next
round of mutagenesis and selection. The mRNA that was
generated from each of the variants was mixed together in
equal proportions and taken through a second round of
mutagenesis and selection as outlined previously with
round one. Resistant clones from the second round had a
MIC of at least 200 ug/ml (the highest concentration of
cefotaxime tested) constituting a minimum 10,000-fold
increase in cefotaxime resistance. Again, ten clones were
sequenced with all clones carrying in combination with
the round 1 mutations E104K and G238S, an extra muta-
tion, M182T (T->C transition) with no silent or other
Coupling Qβ replicase mutagenesis to ribosome displayFig re 2
Coupling Qβ replicase mutagenesis to ribosome display. The UTR, target gene, and CL region are cloned in the reverse 
orientation (frame 2) relative to the T7 promoter and the RQ 135-1(-) sequence to avoid intrinsic stop codons found in the 
modified RQ 135-1(-) sequence. Stop codons are found in frames 1 and 3 of the 5' segment and in all 3 frames of the 3' segment 
of the RQ 135-1(-) sequence (indicated by grey arrows and the script F1 indicating frame 1 etc.). The absence of stop codons 
downstream from the translational start signal is an essential requirement of ribosome display. The pathway is as follows; the 
SmaI digested plasmid is used as a template for transcribing mRNA via the T7 promoter sequence. Although the UTR-target 
gene-CL message is in the reverse orientation and not suitable for translation, the RQ 135-1(-) sequence is in the correct orien-
tation for efficient recognition by Qβ replicase. The resulting mRNA becomes the template for Qβ replicase. Amplification of 
this mRNA template with Qβ replicase generates both (-) and (+) mRNA. The mRNA in the correct orientation for translation 
is coupled to ribosome display to produce a protein complex (target gene + CL + RQ 135-5') that remains tethered to the 
ribosome due to the absence of a stop codon.
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Translate Target protein + CL + RQ135 (5’)
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previous studies of β-lactamase evolution [23]. Interesting
to note that two of the key amino acid mutations resulted
from G->A substitutions which would be well represented
in a Qβ replicase generated library (~30% of total muta-
tions) and less frequent with error-prone PCR (~11% of
the total mutations) or Mut II (~20% of the total muta-
tions).
Note that control experiments performed with mRNA
treated in an identical fashion to that described above,
however, not mutated with Qβ replicase, did not yield any
cefotaxime resistant variants at the concentrations of cefo-
taxime used for selection.
Coupling RNA-based mutagenesis to ribosome display
Qβ replicase-generated mRNA libraries were directly cou-
pled to ribosome display and used to successfully affinity
mature a number of small protein ligands (a single exam-
ple is presented here with the details of the others to be
published elsewhere). Described here is the affinity opti-
mization of a VNAR that is based on the antibody-like Ig
new antigen receptor unique to sharks [24]. These single
domain antibody-like fragments have been reported to
bind to their targets via a single, long, finger like loop
(analogous to CDR3 of antibodies). A VNAR II family
member, 12Y-2, originally isolated by Nuttall and cow-
orkers [25], binds to AMA-1, a single, trans-membrane
domain protein that is thought to be essential for binding
and penetration of the Plasmodium falciparum (malaria)
parasite (merozoite) into red blood cells [26]. Peptides
that bind to AMA-1 have been shown to prevent mero-
zoite invasion [27] suggesting that AMA-1 binders such as
12Y-2 may be biologically useful tools. 12Y-2, however,
has only a modest affinity for AMA-1 in the order of 358
nM (KD) making it an ideal candidate for affinity matura-
tion.
The protein-coding sequence of 12Y-2 was cloned into the
mutagenesis/ribosome display plasmid pEGX253, tran-
scribed to synthesize mRNA, and the mRNA subsequently
mutated with Qβ replicase. The mutated mRNA was used
directly in ribosome display. One round of selection via
ribosome display was performed; the mRNA was recov-
ered and cloned into an expression vector and trans-
formed into E. coli. A total of 200 clones were analyzed for
binding to AMA-1 by ELISA. A range of variants with affin-
ity increases in the order of 3–7-fold were recovered. One
of these clones contained a single mutation K61R (T->A
transversion) mapping to framework region 3. This vari-
ant was subjected to a second round of Qβ replicase muta-
genesis and selection via ribosome display, and again, a
total of 200 round 2 clones were analyzed. The best vari-
ant identified after this second round (clone 1A-13) had a
22-fold increase in binding affinity (a KD of 16 nM) com-
pared with the 12Y-2 parent molecule with an approxi-
mate 2-fold increase in the association rate and a 13-fold
increase in the dissociation rate [28]). 1A-13 contained
two mutations; the parent K61R mutation (isolated in the
first round) and P90L (resulting from a C->T transition)
generated in the second round. The P90L mutation has
also been recently described by Nuttall and co-workers
[25] and maps to the CDR3-like region. Western blot
analysis and gel filtration chromatography indicated that
the expression and monomeric state of 1A-13 appeared
unchanged from the starting 12Y-2 parent (data not
shown).
Discussion
In this report, we have outlined an RNA mutagenesis
method that was specifically developed to provide an
improved approach for the in vitro evolution of proteins,
in particular, as an effective tool that can be coupled to
ribosome display. The RNA-based method is as simple
and convenient as PCR to perform and generates a close
to ideal random mutational spectrum. Further, Qβ repli-
case is not only error prone, but also highly processive and
productive [29] with reactions containing 1 ng of recom-
binant template mRNA yielding over 1 μg of double-
stranded RNA product in 30 minutes. Consequently,
amplification and mutation can be achieved rapidly in a
single step.
Distribution of point mutations along the 500 bp RGSFigure 3
Distribution of point mutations along the 500 bp RGS. The spread of Qβ replicase generated mutations along the 
length of the RGS indicated that Qβ replicase substituted bases randomly across the full length of the RGS mRNA template 
with no obvious mutational hot-spots. A total of 41,280 bases were sequenced and all point mutations identified were plotted.
RGS DNA length (1-500 nucleotides)
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The mutational spectrum of Qβ replicase, Mut II, and EP-PCRFigure 4
The mutational spectrum of Qβ replicase, Mut II, and EP-PCR. (A): Qβ replicase did not have significant bias for A/T-
>N/N (black bars) or G/C->N/N (grey bars) changes. Mut II and EP-PCR using either Mn2+ (manufacture's protocol 3) or Mn2+ 
with an unbalanced dGTP concentration (manufacture's protocol 7) demonstrated significant A/T->N/N bias. (B): The differ-
ent transition/transversion ratios between the methods. Qβ replicase and Mut II did not show a significant bias for transitions 
(black bars) over transversions (grey bars) compared to both versions of EP-PCR, which showed a significant preference for 
transitions. (C): The percentage of all possible base substitutions for each of the mutagenesis methods analyzed. All possible 
base substitutions were recovered with Qβ replicase. The G/C -> C/G transversion was only recovered once with Mut II, 
which also over represented A/T-> T/A transversions. With EP-PCR (manufacture's protocol 3) A/T-> T/A transversions were 
over represented, the A/T->C/G transversion was only recovered once and the G/C -> C/G transversion was not recovered. 
G/C -> C/G and G/C->T/A transversions were not recovered with EP-PCR (manufacture's protocol 7). Both versions of EP-
PCR over represented A/T->G/C transitions. Experiments were repeated 2 times with the standard deviation between exper-
iments shown as error bars. The data set used to generate Figure 3 was as follows: 71 point mutations were characterized for 
Qβ replicase (52,327 bases were sequenced in total with an average mutation rate of 1 point mutation every 737 bases giving a 
mutation frequency of 1.35). 48 point mutations were characterized for Mut II (6720 bases were sequenced in total with a 
mutation rate of 1/140 bases giving a mutation frequency of 7.14). EP-PCR manufacture's protocol 3; 74 point mutations were 
characterized (36,960 bases were sequenced in total with a mutation rate of 1/499 bases and a mutation frequency of 2.00) and 
manufacture's protocol 7; 43 point mutations were characterized (9,600 bases were sequenced in total with a mutation rate of 
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BMC Biotechnology 2007, 7:18 http://www.biomedcentral.com/1472-6750/7/18As a practical demonstration of the effectiveness of the
mRNA libraries generated with Qβ replicase, we used the
method to alter the substrate specificity of β-lactamase.
Several other groups have evolved β-lactamase using a
variety of mutagenesis approaches in an attempt to
increase the ability of the enzyme to hydrolyze cefotax-
ime. These studies serve as a solid basis for the evaluation
of the data presented here. A comparison is reasonably
straight forward as the downstream selection for
improved cefotaxime resistance is based on a simple func-
tional assay for growth on an agar plate in the presence of
increasing concentrations of cefotaxime, which is
expected to be equivalent between laboratories.
As noted above, the cefotaxime MIC for E. coli carrying a
wild-type β-lactamase plasmid is typically around 0.02
ug/ml. In one of the early examples of β-lactamase protein
engineering, Palzkill & Botstein [23] used cassette muta-
genesis to isolate variants with a maximum MIC of 0.64
ug/ml. Later, Stemmer [30] used three rounds of DNA
shuffling and 2 rounds of back-crossing to yield a TEM-1
variant with an MIC of 640 ug/ml. This cefotaxime resist-
ant mutant contained six amino acid changes (including
E104K, G238S and M182T) and an engineered promoter
mutation located between the -35 and -10 sites of the β-
lactamase P3 promoter that increased β-lactamase expres-
sion levels by 2–3-fold. Finally, Zaccolo and Gherardi [31]
isolated TEM-1β-lactamase variants with activity against
cefotaxime that was reported to be 20,000-fold higher
(~400 ug/ml) than wild-type TEM-1 by screening small
pools of hyper-mutated clones (<1.5 × 105) from libraries
containing up to 27 nucleotide substitutions per gene.
Zaccolo and Gherardi [31] required 3 rounds of mutagen-
esis and selection to isolate clones containing the muta-
tions E104K, G238S and M182T, 2 silent mutations, and
a mutation in the pBR322 promoter region. We presume
that our second round clones isolated in this study were
comparable to the highly resistant Zaccolo and Gherardi
clone since the same amino acid substitutions were
selected in both studies (notwithstanding the promoter
mutation and the copy number difference between the
pBR322 plasmid used by Zaccolo and Gherardi and the
pUC19 plasmid used in this study). Interesting to note
that the unselected TEM-1 libraries of Zaccolo and Gher-
ardi contained a mean mutation frequency of 8.2 and
27.2 substitutions per gene length, however, clones
selected on the basis of cefotaxine resisitance showed only
1–11 mutations at the DNA level. It is clear that although
increasing the mutation rate allowed a greater diversity to
be sampled, it was from the sequences that carried the
least number of mutations that functional variants were
isolated [10].
This report highlights the efficiency of the Qβ replicase
RNA methodology. Comparable cefotaxime resistant var-
iants were selected relatively quickly (only two rounds of
mutagenesis and selection) and with no silent or other
superfluous mutations, an approach that was accom-
plished through what we have termed a "minimal muta-
tional pathway". This approach is based on the premise
that a small number of key amino acid substitutions at
crucial positions can have a dramatic effect on the proper-
ties of the protein. This type of strategy can only be suc-
cessfully applied when a low, unbiased mutation
frequency is used to generate a large number of extremely
diverse variants that allow for complete sampling of the
immediate sequence space neighborhood. Moore and
Maranas [9] noted that base substitution bias introduced
by Taq DNA polymerase under error-prone conditions
would render some variants more likely than others, effec-
tively reducing the overall library diversity. Patrick and
coworkers hypothesised [10] that given that directed evo-
lution is most likely to identify an improved variant when
a library is maximally diverse, this would certainly be the
case when all variants in a library are equally probable.
The minimal mutational pathway also provides a number
of other significant advantages. Due to the relatively low
mutation rate, variants have few, if any superfluous or
silent base changes, ensuring that a significant fraction of
the variant pool being screened is functional. By minimiz-
ing the introduction of unnecessary amino acid changes,
the method also avoids collateral damage to proteins.
Unnecessary amino acid substitutions can have signifi-
cant negative effects on a target protein including
increased immunogenicity [32-34], a reduction in expres-
sion level and protein stability [35], amongst others. In
particular, altering the immunogenicity status of a protein
can have a significant downstream impact on the effec-
tiveness of a product as a potential therapeutic [36].
Without doubt, one of the significant advantages of a
RNA-based mutagenesis strategy is the potential to convey
variant mRNA libraries directly into selection approaches
such as ribosome display with little intervention, there-
fore maintaining maximum library diversity during the
selection process. The effectiveness of Qβ replicase-gener-
ated mRNA libraries coupled to ribosome display was
demonstrated by affinity maturing 12Y-2. Two discrete
rounds of Qβ replicase mutagenesis and ribosome display
yielded the 1A-13 mutant that showed a 22-fold increase
in binding to AMA-1 relative to the 12Y-2 parent mole-
cule. 12Y-2 has also been affinity-matured by Nuttall and
colleagues [25] using EP-PCR and 3 rounds of selection
via phage display. This group isolated several mutants of
12Y-2 with the best of these variants carrying the P90L
mutation and showing an 8-fold enhanced affinity for
AMA-1.Page 8 of 12
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replicase mutagenesis approach, the 1A-13 example is
also highlighted here to illustrate the potential difficulties
that challenge directed antibody or protein engineering
strategies that focus mutagenesis on predicted target con-
tact regions alone. The structure of 12Y-2 has recently
been published and the authors suggest that the binding
of 12Y-2 is essentially mediated via the relatively long
CDR3-equivalent loop [37,38]. While amino acid 90 falls
within the expected attachment region in this loop, the
K61R mutation is situated along the exposed flank of the
VNAR, apparently outside the antigen-binding paratope.
Our finding suggests that the K61R mutation may either
rotate or flex CDR3 and improve the interaction of CDR3
with AMA-1 or that this distal exposed site may in fact
have a significant functional role in the binding interac-
tion by making contact with peripheral remote locations
on AMA-1 relative to the epitope targeted by CDR3 [28].
Potentially, the K61R mutation may fall within an addi-
tional hyper-variable region that forms a belt around the
periphery of the molecule [39]. This additional hyper-var-
iable region may be an important consideration when
engineering the affinity of IgNARs in general. Certainly, a
directed protein engineering approach exclusively target-
ing the extended CDR3 loop would not have identified
the 1A-13 variant.
Conclusion
The success of the minimal mutation pathway approach
to protein optimization presented here may be pertinent
in light of the debate in the literature over the benefits of
exploiting large random libraries created at a low muta-
tion frequency versus smaller libraries manufactured
using saturation mutagenesis [31]. Our data suggests that
the nature and diversity of mutations generated within a
gene library governs the outcome, and not the mutation
frequency per se- the wider the spectrum of single amino
acid variations that are generated along the gene length
(achieved through unbiased nucleotide substitutions),
which can then be sampled from a library, the more likely
that the best possible amino acid changes required for
improving protein properties will be identified. The prac-
tical implications of our results are that suitable improved
protein candidates generated through in vitro protein opti-
mization technologies can be selected using significantly
fewer rounds of mutagenesis and selection, and with little
or no collateral damage to the protein or its mRNA.
Methods
Plasmid construction
A multi-cloning site comprising of XhoI, SacII, NotI, NcoI,
SfiI and XhoI was inserted into a highly modified RQ 135-
1(-) sequence [16,17] essentially dividing RQ 135-1(-) into
a 5' end and a 3' end with the multi-cloning site buried in
the middle of the sequence. PCR was used to add a HindIII
site and T7 promoter region to the 5' end, and a SmaI site
to the 3' terminus of the RQ 135-1(-) sequence. The con-
struct was inserted into the HindIII and SmaI sites of
pUC18 (New England Biolabs). This plasmid was desig-
nated pEGX216. The following elements were added to
pEGX216 to construct pEGX253, which was used to gen-
erate mRNA for Qβ replicase mutagenesis and subsequent
ribosome display. A 510 base-pair 5'-UTR followed by a
complete Kozak sequence was added via the SfiI and NcoI
sites; the target gene (in this case, the 12Y-2 coding
sequence) was inserted between the NcoI (also serving as
the start codon) and NotI sites; and directly downstream
of the target gene (between the NotI and SacII sites) was
inserted a 316 bp fragment of the mouse antibody con-
stant light chain (CL) devoid of stop codons that served to
link the newly synthesized protein to the ribosome com-
plex during ribosome display.
Generating RNA template suitable for Qβ replicase
To generate an mRNA template suitable for Qβ replicase,
plasmids (either pEGX216 or pEGX253) were linearized
with SmaI to generate a blunt end fragment that termi-
nates with CCC at the 3' end of the RQ 135-1(-) sequence.
As T7 polymerase initiates transcription with GGG, the
resulting mRNA transcripts contained both the 5'-GGG
and 3'-CCC termini thought to be essential elements for
template recognition by Qβ-replicase [19]. T7 polymerase
often inserts a terminal A nucleotide to the 3' CCC
sequence, however, this did not appear to significantly
influence RNA template recognition. Run off transcrip-
tion on the linear DNA template was performed by adding
40 mM Tris-HCl (pH 7.9), 6 mM MgCl2, 2 mM spermi-
dine, 10 mM dithiothreitol, 1 mM each of rCTP, rUTP,
rGTP, and rATP, 2 U RNase inhibitor (Promega), 20 U T7
polymerase (Promega) to 200 ng DNA template and incu-
bating at 37°C overnight. RNA was DNase-treated to
remove the DNA template (RQ1 DNase, Promega) and
purified (RNeasy, Qiagen) prior to amplification with Qβ
replicase.
Qβ replicase reaction
100 ng of mRNA was pre-heated for 2 min at 95°C in a
thermocycler and permitted to cool slowly to room tem-
perature. The mRNA was mixed with 40 mM Tris-HCl (pH
7.9), 21 mM MgCl2, 2 mM spermidine, 10 mM dithioth-
reitol, 1 mM each of rCTP, rUTP, rGTP, and rATP, 2 U
RNase inhibitor (Promega) and 200 nM Qβ replicase
(prepared in house following the method of Moody et al.
[40]) and incubated for a minimum of 120 min at 37°C.
Qβ replicase products were visualized by combining 5 ul
of the Qβ replicase reaction with loading buffer (Invitro-
gen), and separated via elecrophoresis on 1% agarose gels
containing ethidium bromide. The remaining mRNA was
purified (RNeasy; Qiagen) to remove excess MgCl2prior to
ribosome display.Page 9 of 12
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The mutation frequency and nucleotide bias of Qβ repli-
case was measured using mRNA transcribed from the RGS
DNA which was imbedded into the RQ 135-1(-) sequence
of pEGX216 using the XhoI restriction sites. The plasmid
was linearized with SmaI and was used in a transcription
reaction to generate mRNA template suitable for Qβ rep-
licase. The mRNA template was amplified with Qβ repli-
case and subsequently reverse transcribed and PCR-
amplified (Superscript III™ RT-PCR; Invitrogen) prior to
blunt-end cloning into pPCR-Script Amp SK (+) (Strata-
gene), transformed into E. coli strain HB2151, and clones
chosen at random were sequenced. The control reaction
was processed as outlined above, however, the mRNA was
not amplified with Qβ replicase.
Error-prone PCR (Diversify PCR Random Mutagenesis
Kit; Clontech Laboratories) using the manufacture's pro-
tocol 3 (containing 320 uM Mn2+ and 40 uM dGTP) and
protocol 7 (containing 640 uM Mn2+ and an unbalanced
dGTP concentration of 120 uM) and Mut II (GeneMorph
II Random Mutagenesis Kit; Stratagene) were used to
mutate RGS DNA closely following the protocols outlined
by the manufacturers. The total amount of target template
for each reaction was 1 ng with reactions adjusted to give
approximately a 1000-fold amplification (total yield/tem-
ple amount). Mutated DNA was subsequently cloned into
pPCR-Script Amp SK(+), and as above, transformed into
E. coli, and random clones sequenced. Since it was not
possible to differentiate which of the nucleotide pair was
misincorportated during Qβ replicase amplification and
subsequent RT-PCR, all possible nucleotide substitutions
were grouped into six complementary categories. The
mutation rate was measured from a total of three replicate
experiments for each method. The data is presented as
mutation frequency (number of nucleotide substitutions
per kb), with a minimum of 40 base substitutions charac-
terized for each method.
Evolution of β-lactamase
The TEM-1 β-lactamase gene was cloned into pEGX216
via the XhoI restriction sites, mRNA was transcribed via the
T7 promoter, and the mRNA subsequently mutated with
Qβ replicase. One ng (approximately 1011 molecules) of
mutated mRNA was converted to cDNA and amplified
using high fidelity RT-PCR and gene specific primers. The
entire RT-PCR reaction was purified, restricted with NcoI
and NotI and ligated into 25 ng of a modified pUC19 vec-
tor (New England Biolabs) to replace the wild-type TEM-
1 gene. The modified pUC19 vector was constructed by
generating NcoI and NotI sites at the terminal ends of the
pUC19 wild-type TEM-1 gene sequence by site directed
mutagenesis (QuickChange Mutagenesis) to allow the
wild-type TEM-1 gene to be deleted (leaving the original
upstream regulating sequences intact). 10 ng of the cloned
DNA was used to transform E. coli XL10-Gold cells (Strat-
agene) with an estimated transformation efficiency 5 ×
109 colonies per ug pUC19 DNA. The entire transforma-
tion mix (potentially representing a library of approxi-
mately 107 variants) was plated onto solid nutrient media
containing cefotaxime (Sigma) concentrations of either 5,
10 or 20 ug/ml. As cefotaxime resistance on solid media is
cell-density-dependant, colony numbers were standard-
ized to 300–500 colonies per plate and grown at 37°C for
30 h. Plasmid DNA from resistant clones that grew on the
cefotaxime supplemented media was extracted and
sequenced. The DNA from the best clones from the first
round of mutagenesis and selection were taken through a
second round of mutagenesis and selection by digesting
the plasmid DNA of the individual clones with NcoI and
NotI and ligating back into pEGX216. The plasmids were
then mixed in equal proportions to repeat the mutagene-
sis and selection process. Second round variants were
selected on solid nutrient media containing cefotaxime
concentrations of either 50, 100 or 200 ug/ml. A control
experiment run in parallel was identical with the omission
of the Qβ replicase mutagenesis step.
Ribosome display
Ribosome display was performed by adding 2 ug of heat
denatured Qβ replicase mutated mRNA (heated to 75°C
for 2 min and then cooled rapidly to 4°C) to a 50 ul rabbit
reticulocyte based translation reaction (Flexi rabbit reticu-
locyte lysate system; Promega) in an RNase-free microfuge
tube (Ambion) following the manufacturer's recommen-
dations and allowing translation to proceed for 25 min at
30°C before diluting the translation mix with the addi-
tion of RNase-free, biotin-free skim milk (4% w/v), PBS,
and 5 mM MgCl2 [11,12,41]. 1 nM biotinylated AMA-1
(biotinylated with EZ-Link™ Sulfo-NHS-LC-Biotin;
Pierce) was added directly to the diluted translation mix
in the microfuge tube and rocked on ice for 5 h prior to
the addition of 2000 nM AMA-1. The mix was rocked on
ice for a further 2 h. Ribosome complexes that remained
attached to the biotinylated AMA-1 were recovered with
streptavidin coated magnetic beads (Dynal). Beads were
subsequently washed three times each with PBS contain-
ing 5 mM MgCl2 and 0.01% Tween 20 and two times with
PBS containing 5 mM MgCl2 before being re-suspended in
40 ul dH2O that had been pre-heated to 65°C to disrupt
the ribosome complexes. The beads were removed and the
supernatant was used directly in RT-PCR to recover mRNA
using vector specific primers. The RT-PCR product was gel
purified (Qiagen), digested with NcoI and NotI and ligated
into pGC FLAG/HIS for expression and analysis [42]. The
DNA from designated round 1clones that were to be taken
into a second round of mutagenesis and selection were
ligated into pEGX253 and processed as outlined above
with round 1. Second round panning incorporated
increased selection pressure by increasing the incubationPage 10 of 12
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ond round of mutagenesis and panning, 500 individual
clones were again analysed. Bacterial periplasmic expres-
sion and analysis (ELISA and biosensor binding) of 12Y-
2 clones were as outlined previously [23].
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